Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343432 | 0.82 | MAPT (0.33) | MAPTESR1ESR2MEN1KMT2A | |
| SCHEMBL9773556 | 0.78 | ESR1 (0.42) | MGAMMAPTESR1ESR2ALDH1A1 | |
| SCHEMBL9773554 | 0.78 | ESR1 (0.42) | MGAMMAPTESR1ESR2ALDH1A1 | |
| SCHEMBL9773562 | 0.78 | ESR1 (0.42) | MGAMMAPTESR1ESR2ALDH1A1 | |
| SCHEMBL8969329 | 0.78 | MGAM (0.48) | MGAMMAPTESR1ESR2TSHR | |
| SCHEMBL8969322 | 0.78 | MGAM (0.48) | MGAMMAPTESR1ESR2TSHR | |
| SCHEMBL29945596 | 0.74 | MGAM (0.40) | MGAMMAPTESR1ESR2 | |
| SCHEMBL453982 | 0.73 | NR1H2 (0.48) | MGAMMAPTESR1ESR2ALDH1A1 | |
| SCHEMBL9219897 | 0.73 | MGAM (0.39) | MGAMALDH1A1TSHR | |
| SCHEMBL9219901 | 0.73 | MGAM (0.39) | MGAMALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253243-B2 | Organosilicon compounds and method of manufacturing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1754742-A1 | ORGANOSILICON COMPOUND AND METHOD FOR PRODUCING SAME | Japan Science and Technology Agency (JP) | 2007-02-21 | — | — | EP | disclosed |
| US-20060281890-A1 | Organosilicon compounds and method of manufacturing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281890-A1 | Organosilicon compounds and method of manufacturing the same | HACL2, FANCF, HDHD5 | MGAM 1455/4885MAPT 3992/4885ESR1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.